{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,15]],"date-time":"2026-08-15T07:38:37Z","timestamp":1786779517474,"version":"build-2736575974"},"reference-count":70,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,27]],"date-time":"2024-05-27T00:00:00Z","timestamp":1716768000000},"content-version":"vor","delay-in-days":1456,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["jacepopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACEP Open"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1002\/emp2.12081","type":"journal-article","created":{"date-parts":[[2020,4,9]],"date-time":"2020-04-09T16:44:59Z","timestamp":1586450699000},"page":"231-237","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"title":["COVID\u201019: A review of therapeutics under investigation"],"prefix":"10.1016","volume":"1","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3242-8530","authenticated-orcid":false,"given":"James C.","family":"Crosby","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew A.","family":"Heimann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel L.","family":"Burleson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brendan C.","family":"Anzalone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan F.","family":"Swanson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas W.","family":"Wallace","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher J.","family":"Greene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1002\/emp2.12081_bb0010","unstructured":"Siobh\u00e1n O'Grady R Coronavirus confirmed in all 50 states and D.C., after West Virginia reports first case; U.S. death toll passes 100. The Washington Post. https:\/\/www.washingtonpost.com\/world\/2020\/03\/17\/coronavirus-latest-news\/. Published March 18, 2020. Accessed March 21, 2020."},{"key":"10.1002\/emp2.12081_bb0015","unstructured":"Clinical Management of Severe Acute Respiratory Infection When Novel Coronavirus (nCoV) Infection Is Suspected. World Health Organization. https:\/\/www.who.int\/publications-detail\/clinical-management-of-severe-acute-respiratory-infection-when-novel-coronavirus-(ncov)-infection-is-suspected. Accessed March 21, 2020."},{"issue":"1","key":"10.1002\/emp2.12081_bb0020","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s13578-020-00404-4","article-title":"SARS\u2010CoV\u20102 and COVID\u201019: The most important research questions","volume":"10","author":"Yuen","year":"2020","journal-title":"Cell Biosci"},{"key":"10.1002\/emp2.12081_bb0025","unstructured":"Fortin J. That \u2018Miracle Cure\u2019 You Saw on Facebook? It Won't Stop the Coronavirus. The New York Times. https:\/\/www.nytimes.com\/2020\/03\/18\/health\/coronavirus-cure-gargle-water.html. Published March 18, 2020. Accessed March 24, 2020."},{"key":"10.1002\/emp2.12081_bb0030","unstructured":"Myth busters. World Health Organization. https:\/\/www.who.int\/emergencies\/diseases\/novel-coronavirus-2019\/advice-for-public\/myth-busters. Accessed March 19, 2020."},{"issue":"10224","key":"10.1002\/emp2.12081_bb0035","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0140-6736(20)30251-8","article-title":"Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding","volume":"395","author":"Lu","year":"2020","journal-title":"Lancet"},{"issue":"10","key":"10.1002\/emp2.12081_bb0040","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1517\/13543776.2013.823159","article-title":"Anti\u2010SARS coronavirus agents: a patent review (2008\u2010present)","volume":"23","author":"Kumar","year":"2013","journal-title":"Expert Opin Ther Pat"},{"key":"10.1002\/emp2.12081_bb0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2020.02.052","article-title":"SARS\u2010CoV\u20102 cell entry depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor","author":"Hoffmann","year":"2020","journal-title":"Cell"},{"key":"10.1002\/emp2.12081_bb0050","doi-asserted-by":"crossref","DOI":"10.1002\/jmv.25754","article-title":"From SARS and MERS CoVs to SARS\u2010CoV\u20102: Moving toward more biased codon usage in viral structural and nonstructural genes","author":"Kandeel","year":"2020","journal-title":"J Med Virol"},{"key":"10.1002\/emp2.12081_bb0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.jinf.2020.02.026","article-title":"COVID\u201019 spike\u2010host cell receptor GRP78 binding site prediction","author":"Ibrahim","year":"2020","journal-title":"J Infect"},{"key":"10.1002\/emp2.12081_bb0060","doi-asserted-by":"crossref","DOI":"10.1007\/s12250-020-00205-6","article-title":"Compensation of ACE2 function for possible clinical management of 2019\u2010nCoV\u2010induced acute lung injury","author":"Wu","year":"2020","journal-title":"Virol Sin"},{"issue":"4","key":"10.1002\/emp2.12081_bb0065","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1007\/s00134-020-05985-9","article-title":"Angiotensin\u2010converting enzyme 2 (ACE2) as a SARS\u2010CoV\u20102 receptor: molecular mechanisms and potential therapeutic target","volume":"46","author":"Zhang","year":"2020","journal-title":"Intensive Care Med"},{"key":"10.1002\/emp2.12081_bb0070","article-title":"Dysregulation of immune response in patients with COVID\u201019 in Wuhan, China","author":"Qin","year":"2020","journal-title":"Clin Infect Dis."},{"key":"10.1002\/emp2.12081_bb0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2020.102433","article-title":"The epidemiology and pathogenesis of coronavirus disease (COVID\u201019) outbreak","volume":"109","author":"Rothan","year":"2020","journal-title":"J Autoimmun"},{"key":"10.1002\/emp2.12081_bb0080","unstructured":"Zimmer C.Hundreds of Scientists Scramble to Find a Coronavirus Treatment. The New York Times. https:\/\/www.nytimes.com\/2020\/03\/17\/science\/coronavirus-treatment.html. Published March 17, 2020. Accessed March 24, 2020."},{"issue":"3","key":"10.1002\/emp2.12081_bb0085","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/s41422-020-0282-0","article-title":"Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019\u2010nCoV) in vitro","volume":"30","author":"Wang","year":"2020","journal-title":"Cell Res"},{"issue":"12","key":"10.1002\/emp2.12081_bb0090","doi-asserted-by":"crossref","first-page":"6771","DOI":"10.1073\/pnas.1922083117","article-title":"Prophylactic and therapeutic remdesivir (GS\u20105734) treatment in the rhesus macaque model of MERS\u2010CoV infection","volume":"117","author":"de Wit","year":"2020","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"396","key":"10.1002\/emp2.12081_bb0095","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aal3653","article-title":"Broad\u2010spectrum antiviral GS\u20105734 inhibits both epidemic and zoonotic coronaviruses","volume":"9","author":"Sheahan","year":"2017","journal-title":"Sci Transl Med"},{"key":"10.1002\/emp2.12081_bb0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.105933","article-title":"Arguments in favour of remdesivir for treating SARS\u2010CoV\u20102 infections","author":"Ko","year":"2020","journal-title":"Int J Antimicrob Agents"},{"issue":"10","key":"10.1002\/emp2.12081_bb0105","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1056\/NEJMoa2001191","article-title":"First case of 2019 novel coronavirus in the United States","volume":"382","author":"Holshue","year":"2020","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1002\/emp2.12081_bb0110","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1056\/NEJMoa1910993","article-title":"A randomized, controlled trial of Ebola virus disease therapeutics","volume":"381","author":"Mulangu","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1002\/emp2.12081_bb0115","unstructured":"Adaptive COVID\u201019 Treatment Trial (ACTT) \u2010 Full Text View \u2010 ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04280705?cond=NCT04280705&draw=2&rank=1. Accessed March 24, 2020."},{"issue":"4","key":"10.1002\/emp2.12081_bb0120","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.ijantimicag.2007.05.015","article-title":"Recycling of chloroquine and its hydroxyl analogue to face bacterial, fungal and viral infections in the 21st century","volume":"30","author":"Rolain","year":"2007","journal-title":"Int J Antimicrob Agents"},{"key":"10.1002\/emp2.12081_bb0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.105938","article-title":"New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID\u201019?","author":"Devaux","year":"2020","journal-title":"Int J Antimicrob Agents"},{"issue":"3","key":"10.1002\/emp2.12081_bb0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.105923","article-title":"Chloroquine for the 2019 novel coronavirus SARS\u2010CoV\u20102","volume":"55","author":"Colson","year":"2020","journal-title":"Int J Antimicrob Agents"},{"issue":"1","key":"10.1002\/emp2.12081_bb0135","doi-asserted-by":"crossref","first-page":"72","DOI":"10.5582\/bst.2020.01047","article-title":"Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID\u201019 associated pneumonia in clinical studies","volume":"14","author":"Gao","year":"2020","journal-title":"Biosci Trends"},{"key":"10.1002\/emp2.12081_bb0140","doi-asserted-by":"crossref","unstructured":"Chen Z, Hu J, Zhag Z, et\u00a0al. Efficacy of hydoxychloroquine in patients with COVID\u201019: results of a randomized clinical trial. medRxiv. https:\/\/doi.org\/10.1101\/2020.03.22.20040758","DOI":"10.1101\/2020.03.22.20040758"},{"key":"10.1002\/emp2.12081_bb0145","unstructured":"COVID\u201019 Clinical Trial Launches at University of Minnesota. Medical School \u2010 University of Minnesota. https:\/\/med.umn.edu\/news-events\/covid-19-clinical-trial-launches-university-minnesota. Published March 17, 2020. Accessed March 25, 2020."},{"key":"10.1002\/emp2.12081_bb0150","unstructured":"Chloroquine Prevention of Coronavirus Disease (COVID\u201019) in the Healthcare Setting \u2010 Full Text View \u2010 ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04303507. Accessed March 25, 2020."},{"issue":"4","key":"10.1002\/emp2.12081_bb0155","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1172\/JCI138003","article-title":"The convalescent sera option for containing COVID\u201019 [published online ahead of print, 2020 Mar 13]","volume":"130","author":"Casadevall","year":"2020","journal-title":"J Clin Invest"},{"issue":"4","key":"10.1002\/emp2.12081_bb0160","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/S1473-3099(20)30141-9","article-title":"Convalescent plasma as a potential therapy for COVID\u201019 [published online ahead of print, 2020 Feb 27]","volume":"20","author":"Chen","year":"2020","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"10.1002\/emp2.12081_bb0165","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.transci.2016.12.014","article-title":"Use of convalescent plasma in Ebola virus infection","volume":"56","author":"Garraud","year":"2017","journal-title":"Transfus Apher Sci"},{"issue":"25","key":"10.1002\/emp2.12081_bb0170","first-page":"2500","article-title":"Convalescent plasma for Ebola virus disease","volume":"374","author":"van Griensven","year":"2016","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1002\/emp2.12081_bb0175","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1093\/infdis\/jiu396","article-title":"The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta\u2010analysis","volume":"211","author":"Mair\u2010Jenkins","year":"2015","journal-title":"J Infect Dis"},{"key":"10.1002\/emp2.12081_bb0180","doi-asserted-by":"crossref","unstructured":"Shen C, Wang Z, Zhao F, et\u00a0al. Treatment of 5 critically ill patients with COVID\u201019 with convalescent plasma. JAMA. Published online March 27, 2020 https:\/\/doi.org\/10.1001\/jama.2020.4783","DOI":"10.1001\/jama.2020.4783"},{"key":"10.1002\/emp2.12081_bb0185","unstructured":"Anti\u2010SARS\u2010CoV\u20102 Inactivated Convalescent Plasma in the Treatment of COVID\u201019 \u2010 Full Text View. ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04292340?term=convalescent+plasma&cond=COVID-19&draw=2&rank=1. Accessed March 24, 2020."},{"key":"10.1002\/emp2.12081_bb0190","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1136\/thorax.2003.012658","article-title":"Role of lopinavir\/ritonavir in the treatment of SARS: initial virological and clinical findings","volume":"59","author":"Chu","year":"2004","journal-title":"Thorax"},{"key":"10.1002\/emp2.12081_bb0195","first-page":"399","article-title":"Treatment of severe acute respiratory syndrome with lopinavir\/ritonavir: a multicenter retrospective matched cohort study","volume":"9","author":"Chan","year":"2003","journal-title":"Hong Kong Med J"},{"issue":"2","key":"10.1002\/emp2.12081_bb0200","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1016\/j.jgg.2020.02.001","article-title":"Potential inhibitors against 2019\u2010nCoV coronavirus M protease from clinically approved medicines","volume":"47","author":"Liu","year":"2020","journal-title":"J Genet Genomics"},{"key":"10.1002\/emp2.12081_bb0205","first-page":"1","article-title":"A systemic review of lopinavir therapy for SARS coronavirus and MERS coronavirus\u2014a possible reference for coronavirus disease\u201019 treatment option","author":"Yao","year":"2020","journal-title":"J Med Virol"},{"issue":"5","key":"10.1002\/emp2.12081_bb0210","article-title":"Pneumonia imported into Korea from Wuhan, China: implication for infection prevention and control measures","volume":"35","author":"Kim","year":"2020","journal-title":"J Korean Med Sci"},{"issue":"6","key":"10.1002\/emp2.12081_bb0215","doi-asserted-by":"crossref","DOI":"10.3346\/jkms.2020.35.e79","article-title":"Case of the index patient who caused tertiary transmission of coronavirus disease 2019 in Korea: the application of lopinavir\/ritonavir for the treatment of COVID\u201019 pneumonia monitored by quantitative RT\u2010PCR","volume":"35","author":"Lim","year":"2020","journal-title":"J Korean Med Sci"},{"key":"10.1002\/emp2.12081_bb0220","doi-asserted-by":"crossref","DOI":"10.1001\/jama.2020.3204","article-title":"Epidemiologic features and clinical course of patients infected with SARS\u2010CoV\u20102 in Singapore","author":"Young","year":"2020","journal-title":"JAMA"},{"issue":"10","key":"10.1002\/emp2.12081_bb0225","doi-asserted-by":"crossref","first-page":"997","DOI":"10.2174\/092986708784049658","article-title":"Arbidol: a broad\u2010spectrum antiviral compound that blocks viral fusion","volume":"15","author":"Boriskin","year":"2008","journal-title":"Curr Med Chem"},{"key":"10.1002\/emp2.12081_bb0230","doi-asserted-by":"crossref","DOI":"10.1016\/j.jinf.2020.03.002","article-title":"Arbidol combined with LPV\/r versus LPV\/r alone against corona virus disease 2019: a retrospective cohort study","author":"Deng","year":"2020","journal-title":"J Infection"},{"key":"10.1002\/emp2.12081_bb0235","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2001282","article-title":"A trial of lopinavir\/ritonavir in adults hospitalized with severe Covid\u201019","author":"Cao","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1002\/emp2.12081_bb0240","unstructured":"United States National Library of Medicine Clinical Trials Database. https:\/\/clinicaltrials.gov\/ct2\/results?cond=coronavirus&term=lopinavir%2Fritonavir&cntry=&state=&city=&dist=#wrapper. Accessed March 20, 2020."},{"issue":"7","key":"10.1002\/emp2.12081_bb0245","doi-asserted-by":"crossref","first-page":"3039","DOI":"10.1128\/JVI.01792-08","article-title":"Severe acute respiratory syndrome (SARS) coronavirus\u2010induced lung epithelial cytokines exacerbate SARS pathogenesis by modulating intrinsic functions of monocyte\u2010derived macrophages and dendritic cells","volume":"83","author":"Yoshikawa","year":"2008","journal-title":"J Virol"},{"key":"10.1002\/emp2.12081_bb0250","doi-asserted-by":"crossref","DOI":"10.1002\/jmv.25770","article-title":"Diagnostic utility of clinical laboratory data determinations for patients with the severe COVID\u201019","author":"Gao","year":"2020","journal-title":"J Med Virol"},{"key":"10.1002\/emp2.12081_bb0255","article-title":"Clinical features of 69 cases with coronavirus disease 2019 in Wuhan, China","author":"Wang","year":"2020","journal-title":"Clin Infect Dis."},{"key":"10.1002\/emp2.12081_bb0260","unstructured":"Xu, X.Effective Treatment of Severe COVID 19 Patients with Tocilizumab. ChinaXiv 1\u201312. www.chinaxiv.org. Accessed March 23, 2020."},{"key":"10.1002\/emp2.12081_bb0265","unstructured":"Sanofi and Regeneron begin global Kevzara\u00ae (sarilumab) clinical trial program in patients with severe COVID\u201019 \u2010 Mar 16, 2020. http:\/\/www.news.sanofi.us\/2020-03-16-Sanofi-and-Regeneron-begin-global-Kevzara-R-sarilumab-clinical-trial-program-in-patients-with-severe-COVID-19. Accessed March 24, 2020."},{"issue":"1","key":"10.1002\/emp2.12081_bb0270","doi-asserted-by":"crossref","first-page":"15","DOI":"10.4037\/ajcc2015320","article-title":"Body temperature and mortality in patients with acute respiratory distress syndrome","volume":"24","author":"Schell\u2010Chaple","year":"2015","journal-title":"Am J Crit Care"},{"key":"10.1002\/emp2.12081_bb0275","unstructured":"Willsher K. Anti\u2010inflammatories may aggravate Covid\u201019, France advises. The Guardian. https:\/\/www.theguardian.com\/world\/2020\/mar\/14\/anti-inflammatory-drugs-may-aggravate-coronavirus-infection. Published March 14, 2020. Accessed March 24, 2020."},{"key":"10.1002\/emp2.12081_bb0280","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1172\/JCI27291","article-title":"Biological basis for the cardiovascular consequences of COX\u20102 inhibition: therapeutic challenges and opportunities","volume":"116","author":"Grosser","year":"2006","journal-title":"J Clin Invest"},{"key":"10.1002\/emp2.12081_bb0285","unstructured":"Afp. Updated: WHO Now Doesn't Recommend Avoiding Ibuprofen For COVID\u201019 Symptoms. ScienceAlert. https:\/\/www.sciencealert.com\/who-recommends-to-avoid-taking-ibuprofen-for-covid-19-symptoms. Accessed March 24, 2020."},{"issue":"6485","key":"10.1002\/emp2.12081_bb0290","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1126\/science.abb8034","article-title":"Misguided drug advice for COVID\u201019","volume":"367","author":"Fitzgerald","year":"2020","journal-title":"Science"},{"issue":"10223","key":"10.1002\/emp2.12081_bb0295","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China","volume":"395","author":"Huang","year":"2020","journal-title":"Lancet"},{"issue":"9","key":"10.1002\/emp2.12081_bb0300","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.0030343","article-title":"SARS: systematic review of treatment effects","volume":"3","author":"Stockman","year":"2006","journal-title":"PLoS Med"},{"issue":"6","key":"10.1002\/emp2.12081_bb0305","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1164\/rccm.201706-1172OC","article-title":"Corticosteroid therapy for critically ill patients with Middle East respiratory syndrome","volume":"197","author":"Arabi","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"issue":"9","key":"10.1002\/emp2.12081_bb0310","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1097\/CCM.0000000000003262","article-title":"Corticosteroids in sepsis: an updated systematic review and meta\u2010analysis","volume":"46","author":"Rochwerg","year":"2018","journal-title":"Crit Care Med"},{"issue":"3","key":"10.1002\/emp2.12081_bb0315","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S2213-2600(19)30417-5","article-title":"Dexamethasone treatment for the acute respiratory distress syndrome: a multicentre, randomised controlled trial","volume":"8","author":"Villar","year":"2020","journal-title":"Lancet Respir Med"},{"key":"10.1002\/emp2.12081_bb0320","doi-asserted-by":"crossref","unstructured":"Wu C, Chen X, Cai Y, et\u00a0al. Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China. JAMA Intern Med. Published online March 13, 2020. https:\/\/doi.org\/10.1001\/jamainternmed.2020.0994","DOI":"10.1001\/jamainternmed.2020.0994"},{"key":"10.1002\/emp2.12081_bb0325","doi-asserted-by":"crossref","DOI":"10.1007\/s00134-020-06022-5","article-title":"Surviving sepsis campaign: guidelines on the management of adults with coronavirus disease 2019 (COVID\u201019)","author":"Alhazzani","year":"2020","journal-title":"Intensive Care Med."},{"key":"10.1002\/emp2.12081_bb0330","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00127-20","article-title":"Receptor recognition by novel coronavirus from Wuhan: an analysis based on decade\u2010long structural studies of SARS","author":"Wan","year":"2020","journal-title":"J Virology"},{"issue":"4","key":"10.1002\/emp2.12081_bb0335","doi-asserted-by":"crossref","DOI":"10.1016\/S2213-2600(20)30116-8","article-title":"Are Patients with hypertension and diabetes mellitus at increased risk for COVID\u201019 infection?","volume":"8","author":"Fang","year":"2020","journal-title":"Lancet Respir Med"},{"issue":"2","key":"10.1002\/emp2.12081_bb0340","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.00398-20","article-title":"Hiding in plain sight: an approach to treating patients with severe COVID\u201019 infection","volume":"11","author":"Fedson","year":"2020","journal-title":"mBio"},{"key":"10.1002\/emp2.12081_bb0345","unstructured":"\u201cAdditional Warnings Issued for COVID\u201019 Possible Treatments.\u201d CredibleMeds, crediblemeds.org\/blog\/additional\u2010warnings\u2010issued\u2010covid\u201019\u2010possible\u2010treatments\/."},{"key":"10.1002\/emp2.12081_bb0350","unstructured":"Waldrop, Theresa, and Dave Alsup. \u201cArizona Man Dies after Self\u2010Medicating with Chloroquine to Treat Coronavirus.\u201d CNN, Cable News Network, 24 Mar. 2020, www.cnn.com\/2020\/03\/23\/health\/arizona-coronavirus-chloroquine-death\/index.html."},{"key":"10.1002\/emp2.12081_bb0355","unstructured":"Kupferschmidt K, CohenMar J, VoosenMar P, et\u00a0al. WHO launches global megatrial of the four most promising coronavirus treatments. Science. https:\/\/www.sciencemag.org\/news\/2020\/03\/who-launches-global-megatrial-four-most-promising-coronavirus-treatments. Published March 22, 2020. Accessed March 24, 2020."}],"container-title":["JACEP Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Femp2.12081","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/emp2.12081","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/emp2.12081","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2688115224005095?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2688115224005095?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/emp2.12081","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,25]],"date-time":"2025-01-25T01:01:44Z","timestamp":1737766904000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2688115224005095"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":70,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["S2688115224005095"],"URL":"https:\/\/doi.org\/10.1002\/emp2.12081","relation":{},"ISSN":["2688-1152"],"issn-type":[{"value":"2688-1152","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"COVID\u201019: A review of therapeutics under investigation","name":"articletitle","label":"Article Title"},{"value":"JACEP Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1002\/emp2.12081","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2020 THE AUTHORS. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}